ImmuCell Corporation (ICCC)
NASDAQ: ICCC · Real-Time Price · USD
8.38
+0.13 (1.58%)
At close: Apr 28, 2026, 4:00 PM EDT
8.35
-0.03 (-0.36%)
After-hours: Apr 28, 2026, 4:10 PM EDT
ImmuCell Employees
ImmuCell had 73 employees as of December 31, 2025. The number of employees decreased by 2 or -2.67% compared to the previous year.
Employees
73
Change (1Y)
-2
Growth (1Y)
-2.67%
Revenue / Employee
$378,687
Profits / Employee
-$14,247
Market Cap
75.81M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 142 |
| Pelthos Therapeutics | 92 |
| XBiotech | 85 |
| Fortress Biotech | 78 |
| Acrivon Therapeutics | 76 |
| aTyr Pharma | 60 |
| PMV Pharmaceuticals | 54 |
| Pliant Therapeutics | 49 |
ICCC News
- 15 days ago - ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors - GlobeNewsWire
- 20 days ago - ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results - GlobeNewsWire
- 5 weeks ago - ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board - GlobeNewsWire
- 7 weeks ago - ImmuCell Earnings Call Transcript: Q4 2025 - Transcripts
- 7 weeks ago - ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025 - GlobeNewsWire
- 2 months ago - ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2025 - GlobeNewsWire
- 3 months ago - ImmuCell Earnings Call Transcript: Q4 2025 - Transcripts
- 3 months ago - ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025 - GlobeNewsWire